Retatrutide (5mg)

Retatrutide is the first triple agonist peptide targeting the Glucagon, GLP-1, and GIP receptors (3G). Among its predecessors, Semaglutide (Ozempic, Rybelsus, Wegovy) and Tirzepatide (Mounjaro), Retartrutide is also a GLP-1/GIP and Glucagon/GLP-1 dual receptor co-agonist.  What does this mean?? It’s more potent than either Semaglutide or Tirzepatide with the addition of a pronounced appetite suppressing component feeling It’s the best of them all….

What does this mean in the real world?? Retatrutide is administered subcutaneously, with a half-life of 6 days, and therefore can be injected 1 x weekly. After 48 weeks, Retatrutide achieved 24.2% weight loss in obese or overweight patients and produced 17% weight loss in diabetic patients, making it arguably the most powerful 3G in the pipeline today. In addition, Retatrutide also achieved up to 86% reduction in liver fat in patients with NASH (non-alcoholic steatohepatitis). Quite simply, being overweight is now a choice – just 1 shot a week to make all the fat just melt away…